Evidence map›Paper›PMID 42437048›Full record

ArticleGenes & diseases2026

Optimal combination of immune cells for predicting outcomes in ESCC patients following neoadjuvant immunochemotherapy: Results from a prospective phase II trial.

Peipei Wang, Yueyun Chen, Lin Lu, Yue Zheng, Xia Liu, Haibo Mao, Zexin Yi, Jiajun Li, Qin Zhang, Chengwu Zeng and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes & diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Peipei WangDepartment of Oncology, School of Medicine, the Second Affiliated Hospital of South China University of Technology (Guangzhou First People's Hospital), Guangzhou, Guangdong 510180, China.
Yueyun ChenDepartment of Biotherapy, Cancer Center, West China Hospital, West China Medical School, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan 610041, China.
Lin LuDepartment of Oncology, School of Medicine, the Second Affiliated Hospital of South China University of Technology (Guangzhou First People's Hospital), Guangzhou, Guangdong 510180, China.
Yue ZhengDepartment of Biotherapy, Cancer Center, West China Hospital, West China Medical School, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan 610041, China.
Xia LiuDepartment of Oncology, School of Medicine, the Second Affiliated Hospital of South China University of Technology (Guangzhou First People's Hospital), Guangzhou, Guangdong 510180, China.
Haibo MaoDepartment of Oncology, School of Medicine, the Second Affiliated Hospital of South China University of Technology (Guangzhou First People's Hospital), Guangzhou, Guangdong 510180, China.
Zexin YiDepartment of Oncology, School of Medicine, the Second Affiliated Hospital of South China University of Technology (Guangzhou First People's Hospital), Guangzhou, Guangdong 510180, China.
Jiajun LiDepartment of Oncology, School of Medicine, the Second Affiliated Hospital of South China University of Technology (Guangzhou First People's Hospital), Guangzhou, Guangdong 510180, China.
Qin ZhangDepartment of Postgraduate Students, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
Chengwu ZengDepartment of Hematology, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510700, China.
Yong WuDepartment of Oncology, School of Medicine, the Second Affiliated Hospital of South China University of Technology (Guangzhou First People's Hospital), Guangzhou, Guangdong 510180, China.
Zhenyu DingDepartment of Biotherapy, Cancer Center, West China Hospital, West China Medical School, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan 610041, China.
Cunte ChenDepartment of Hematology, Guangzhou First People's Hospital, Institute of Blood Transfusion and Hematology, Guangzhou Medical University, Guangzhou, Guangdong 510180, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42437048
PMCPMC13355625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.